Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Epidemiology/Health Services Research

Diabetes, Glycated Hemoglobin, and the Risk of Myocardial Infarction in Women and Men: A Prospective Cohort Study of the UK Biobank

  1. Marit de Jong1,
  2. Mark Woodward2,3,4 and
  3. Sanne A.E. Peters1,2,3⇑
  1. 1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
  2. 2The George Institute for Global Health, University of Oxford, Oxford, U.K.
  3. 3The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
  4. 4Department of Epidemiology, Johns Hopkins University, Baltimore, MD
  1. Corresponding author: Sanne A.E. Peters, sanne.peters{at}georgeinstitute.ox.ac.uk
Diabetes Care 2020 Sep; 43(9): 2050-2059. https://doi.org/10.2337/dc19-2363
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Multiple-adjusted rates of MI (per 10,000 person-years) by sex for diabetes status (A) and levels of HbA1c (B). Analyses on diabetes status were adjusted for age, smoking, BMI, systolic blood pressure, use of antihypertensive medication, total cholesterol, use of lipid-lowering medication, and the Townsend social deprivation score, with interaction terms between each variable and sex. Analyses for levels of HbA1c were additionally adjusted for the use of glucose-lowering medication, again with interaction terms between each variable and sex. No previously diagnosed diabetes includes no diabetes, prediabetes, and undiagnosed diabetes. HbA1c 6.5% = 48 mmol/mol; HbA1c 7.5% = 58 mmol/mol. Pre, prediabetes.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Multiple-adjusted sex-specific HRs for MI by diabetes status (reference = no diabetes) (A) and levels of HbA1c (reference = no previously diagnosed diabetes) (B). Analyses on diabetes status were adjusted for age, smoking, BMI, systolic blood pressure, use of antihypertensive medication, total cholesterol, use of lipid-lowering medication, and the Townsend social deprivation score, with interaction terms between each variable and sex. Analyses for levels of HbA1c were additionally adjusted for the use of glucose-lowering medication. No previously diagnosed diabetes includes participants categorized as having no diabetes, prediabetes, and undiagnosed diabetes. HbA1c 6.5% = 48 mmol/mol; HbA1c 7.5% = 58 mmol/mol. Pre, prediabetes.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Multiple-adjusted HRs for MI according to baseline HbA1c, stratified by women (A) and men (B). Penalized spline models with 4 df and reference HbA1c set at 5.3% (34 mmol/mol). Analyses were adjusted for age, smoking, BMI, systolic blood pressure, antihypertensive medication, total cholesterol, use of lipid-lowering medication, Townsend social deprivation score, history of diabetes (no previously diagnosed diabetes, including prediabetes and undiagnosed diabetes), and the use of glucose-lowering medication. Shaded lines show 95% CIs. Vertical lines at HbA1c 5.7% (39 mmol/mol) and 6.5% (48 mmol/mol) show the threshold for prediabetes (Pre) and diabetes, respectively.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    Multiple-adjusted sex-specific HRs and women-to-men RHRs for MI per 1% HbA1c change overall and in subgroups. Analyses were adjusted for age, smoking, BMI, systolic blood pressure, antihypertensive medication, total cholesterol, use of lipid-lowering medication, the Townsend social deprivation score, history of diabetes (no previously diagnosed diabetes, including prediabetes and undiagnosed diabetes), and the use of glucose-lowering medication, with interaction terms between each variable and sex. P values for the sex-specific HRs represent the two-way interaction terms, including HbA1c and the variable that was stratified for. P values for the women-to-men RHRs represent the three-way interaction terms, including sex, HbA1c, and the variable that was stratified for.

Tables

  • Figures
  • Table 1

    Baseline characteristics by sex and diabetes status

    WomenMen
    All (n = 263,024)No diabetes (n = 221,592)Prediabetes (n = 30,939)Undiagnosed diabetes (n = 1,253)Previously diagnosed diabetes (n = 9,240)All (n = 208,375)No diabetes (n = 170,672)Prediabetes (n = 23,486)Undiagnosed diabetes (n = 1,801)Previously diagnosed diabetes (n = 12,416)
    General characteristics
     Age (years)56.2 (8.0)55.6 (8.0)59.8 (6.6)58.9 (6.9)58.3 (7.7)56.3 (8.2)55.7 (8.3)58.6 (7.6)57.3 (7.8)59.4 (7.2)
     Ethnicity
      White247,983 (95)211,266 (96)27,885 (91)1,003 (81)7,829 (86)195,940 (95)162,750 (96)20,864 (90)1,519 (85)10,807 (88)
      Nonwhite/mixed14,006 (5)9,569 (4)2,872 (9)235 (19)1,330 (15)11,271 (5)7,072 (4)2,433 (10)262 (15)1,504 (12)
     SES
      High177,791 (68)152,028 (69)19,949 (65)698 (56)5,116 (55)139,662 (67)116,866 (69)14,636 (62)993 (55)7,167 (58)
      Low84,921 (32)69,310 (31)10,950 (35)553 (44)4,108 (45)68,441 (33)53,594 (31)8,813 (38)803 (45)5,231 (42)
     Smoking
      Never157,131 (60)133,337 (60)17,631 (57)728 (59)5,435 (59)104,685 (50)89,200 (52)9,666 (42)719 (40)5,100 (41)
      Past81,592 (31)69,100 (31)9,184 (30)378 (31)2,930 (32)76,900 (37)61,270 (36)9,175 (39)755 (42)5,700 (46)
      Current23,067 (9)18,222 (8)3,931 (13)131 (11)783 (9)25,752 (12)19,499 (11)4,452 (19)308 (17)1,493 (12)
    Diabetes characteristics
     Diabetes duration (years)NANANANA8.4 (10.0)NANANANA8.5 (10.1)
     Median diabetes duration (years) (IQR)NANANANA5 (2–10)NANANANA5 (2–10)
     Diabetes type 1^NANANANA500 (5)NANANANA531 (4)
     HbA1c (%)5.4 (0.5)5.3 (0.3)5.9 (0.2)7.4 (1.5)6.9 (1.3)5.5 (0.7)5.3 (0.3)5.9 (0.2)7.7 (1.6)7.0 (1.3)
     Median HbA1c (%) (IQR)5.4 (5.1–5.6)5.3 (5.1–5.5)5.8 (5.8–6)6.9 (6.7–7.5)6.7 (6–7.5)5.4 (5.1–5.6)5.3 (5.1–5.5)5.9 (5.8–6)7.1 (6.7–8)6.7 (6.1–7.6)
     HbA1c (mmol/mol)35.7 (5.8)34.0 (3.0)41.0 (1.9)58.0 (16.7)51.8 (14.1)36.2 (7.1)33.9 (3.0)41.1 (2.0)60.8 (17.9)52.8 (13.9)
     Median HbA1c (mmol/mol) (IQR)35.1 (32.7–37.6)34.4 (32.2–36.3)40.4 (39.5–41.9)51.8 (49.5–58.5)49.4 (42.0–58.5)35.1 (32.7–37.8)34.3 (32.1–36.2)40.5 (39.6–42.0)53.6 (49.9–64.3)50.1 (43.2–59.2)
    Measurements
     BMI (kg/m2)27 (5.1)26.5 (4.8)28.8 (5.7)32.7 (6.3)31.8 (6.7)27.7 (4.2)27.3 (3.9)28.9 (4.6)31.4 (5.2)30.7 (5.3)
     Systolic BP (mmHg)135.2 (19.2)134.3 (19.1)140.3 (19.1)146.74 (19.4)139.2 (17.7)141.1 (17.4)140.5 (17.3)143.9 (17.8)147.9 (18.1)142.6 (16.6)
     Diastolic BP (mmHg)80.8 (10)80.5 (10.0)82.4 (9.9)86.3 (10.2)80.9 (9.7)84.5 (9.9)84.4 (9.9)85.6 (9.9)88.8 (10.2)82.6 (9.4)
     Cholesterol (mmol/L)5.9 (1.1)5.9 (1.1)6.1 (1.2)6.1 (1.3)4.8 (1.1)5.6 (1.1)5.7 (1.0)5.6 (1.1)5.7 (1.2)4.4 (1.0)
    Prescribed medication
     Antidiabetic medication
      OralNANANANA4,109 (73)NANANANA6,045 (75)
      InsulinNANANANA834 (15)NANANANA1,015 (13)
      Oral + insulinNANANANA709 (13)NANANANA959 (12)
     Antihypertensive medication32,317 (12)21,483 (10)5,899 (19)281 (22)4,654 (50)32,553 (16)20,265 (12)4,893 (21)384 (21)7,011 (57)
     Lipid-lowering medication23,057 (9)12,680 (5.7)4,583 (15)227 (18)5,567 (60)29,535 (14)16,204 (10)4,664 (20)315 (18)8,352 (67)
    • Data are mean (SD) or n (%) unless otherwise indicated. BP, blood pressure; IQR, interquartile range; NA, not applicable.

    • ↵^ Participants with self-reported diabetes onset before the age of 30 years and using insulin were considered to have type 1 diabetes. Because of missing data, not all variables included add up to n = 208,375 for men and n = 263,024 for women.

PreviousNext
Back to top
Diabetes Care: 43 (9)

In this Issue

September 2020, 43(9)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Diabetes, Glycated Hemoglobin, and the Risk of Myocardial Infarction in Women and Men: A Prospective Cohort Study of the UK Biobank
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Diabetes, Glycated Hemoglobin, and the Risk of Myocardial Infarction in Women and Men: A Prospective Cohort Study of the UK Biobank
Marit de Jong, Mark Woodward, Sanne A.E. Peters
Diabetes Care Sep 2020, 43 (9) 2050-2059; DOI: 10.2337/dc19-2363

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Diabetes, Glycated Hemoglobin, and the Risk of Myocardial Infarction in Women and Men: A Prospective Cohort Study of the UK Biobank
Marit de Jong, Mark Woodward, Sanne A.E. Peters
Diabetes Care Sep 2020, 43 (9) 2050-2059; DOI: 10.2337/dc19-2363
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Conclusions
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Comparisons of Polyexposure, Polygenic, and Clinical Risk Scores in Risk Prediction of Type 2 Diabetes
  • Quantifying Variation in Treatment Utilization for Type 2 Diabetes Across Five Major University of California Health Systems
  • Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Show more Epidemiology/Health Services Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.